Cytochrome P450 2D6 Inhibitors
1 drugsAbout Cytochrome P450 2D6
Cytochrome P450 2D6 (CYP2D6) is an enzyme in the cytochrome P450 superfamily, responsible for metabolizing various compounds, including many drugs. Its activity significantly impacts drug response, influencing efficacy and adverse effect risks due to variations in the CYP2D6 gene.
CYP2D6 is a vital target in drug development, particularly within the central nervous system (CNS) therapeutic area, despite the lack of direct genetic evidence linking CYP2D6 variations to specific diseases. Understanding CYP2D6's influence is paramount for optimizing drug dosages and personalizing treatment strategies.
CYP2D6 is targeted by one FDA-approved drug, AUVELITY, a small molecule developed by AXSOME for CNS indications. AUVELITY was first approved in 2022, representing the sole approved drug targeting CYP2D6 to date.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Overweight with only 1 trials.
Top Cytochrome P450 2D6 Drugs
The competitive landscape is highly concentrated, with AXSOME being the only company with an approved drug.
High market concentration suggests potential entry barriers and the need for differentiated strategies to compete effectively.
Cytochrome P450 2D6 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Cytochrome P450 2D6, using small molecule modality.
The lack of diverse modalities indicates a whitespace opportunity for novel therapeutic approaches like antibodies or biologics.
Cytochrome P450 2D6 Clinical Trials 88 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 29 | 22 | 3 | 4 | 88% |
| Phase 2 | 18 | 15 | 2 | 1 | 88% |
| Phase 3 | 17 | 10 | 2 | 5 | 83% |
| Phase 4 | 24 | 16 | 5 | 3 | 76% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Cytochrome P450 2D6 Drug Approval Timeline (2022 - 2022)
The approval timeline shows that the first and most recent drug, AUVELITY, was approved in 2022.
Recent approval suggests renewed interest in CYP2D6, but saturation may occur quickly without novel approaches.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 65 clinical trials targeting Cytochrome P450 2D6.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities